205 related articles for article (PubMed ID: 12706362)
1. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?
Vrieling C; Collette L; Fourquet A; Hoogenraad WJ; Horiot JC; Jager JJ; Bing Oei S; Peterse HL; Pierart M; Poortmans PM; Struikmans H; Van den Bogaert W; Bartelink H;
Eur J Cancer; 2003 May; 39(7):932-44. PubMed ID: 12706362
[TBL] [Abstract][Full Text] [Related]
2. Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer.
Touboul E; Buffat L; Belkacémi Y; Lefranc JP; Uzan S; Lhuillier P; Faivre C; Huart J; Lotz JP; Antoine M; Pène F; Blondon J; Izrael V; Laugier A; Schlienger M; Housset M
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):25-38. PubMed ID: 9989511
[TBL] [Abstract][Full Text] [Related]
3. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial.
Jones HA; Antonini N; Hart AA; Peterse JL; Horiot JC; Collin F; Poortmans PM; Oei SB; Collette L; Struikmans H; Van den Bogaert WF; Fourquet A; Jager JJ; Schinagl DA; Wárlám-Rodenhuis CC; Bartelink H
J Clin Oncol; 2009 Oct; 27(30):4939-47. PubMed ID: 19720914
[TBL] [Abstract][Full Text] [Related]
4. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.
Bartelink H; Maingon P; Poortmans P; Weltens C; Fourquet A; Jager J; Schinagl D; Oei B; Rodenhuis C; Horiot JC; Struikmans H; Van Limbergen E; Kirova Y; Elkhuizen P; Bongartz R; Miralbell R; Morgan D; Dubois JB; Remouchamps V; Mirimanoff RO; Collette S; Collette L;
Lancet Oncol; 2015 Jan; 16(1):47-56. PubMed ID: 25500422
[TBL] [Abstract][Full Text] [Related]
5. Impact of young age on outcome in patients with ductal carcinoma-in-situ treated with breast-conserving therapy.
Vicini FA; Kestin LL; Goldstein NS; Chen PY; Pettinga J; Frazier RC; Martinez AA
J Clin Oncol; 2000 Jan; 18(2):296-306. PubMed ID: 10637243
[TBL] [Abstract][Full Text] [Related]
6. Conservation therapy in T1-T2 breast cancer: past, current issues, and future challenges and opportunities.
Perez CA
Cancer J; 2003; 9(6):442-53. PubMed ID: 14740972
[TBL] [Abstract][Full Text] [Related]
7. The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial.
Poortmans PM; Collette L; Bartelink H; Struikmans H; Van den Bogaert WF; Fourquet A; Jager JJ; Hoogenraad W; Müller RP; Dubois JB; Bolla M; Van Der Hulst M; Wárlám-Rodenhuis CC; Pierart M; Horiot JC;
Cancer Radiother; 2008 Nov; 12(6-7):565-70. PubMed ID: 18760649
[TBL] [Abstract][Full Text] [Related]
8. Histological determinants for different types of local recurrence after breast-conserving therapy of invasive breast cancer. Dutch Study Group on local Recurrence after Breast Conservation (BORST).
Voogd AC; Peterse JL; Crommelin MA; Rutgers EJ; Botke G; Elkhuizen PH; van Geel AN; Hoekstra CJ; van Pel R; van de Vijver MJ; Coebergh JW
Eur J Cancer; 1999 Dec; 35(13):1828-37. PubMed ID: 10673999
[TBL] [Abstract][Full Text] [Related]
9. Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial.
Poortmans PM; Collette L; Horiot JC; Van den Bogaert WF; Fourquet A; Kuten A; Noordijk EM; Hoogenraad W; Mirimanoff RO; Pierart M; Van Limbergen E; Bartelink H;
Radiother Oncol; 2009 Jan; 90(1):80-5. PubMed ID: 18707785
[TBL] [Abstract][Full Text] [Related]
10. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial.
Polgár C; Ott OJ; Hildebrandt G; Kauer-Dorner D; Knauerhase H; Major T; Lyczek J; Guinot JL; Dunst J; Miguelez CG; Slampa P; Allgäuer M; Lössl K; Polat B; Kovács G; Fischedick AR; Fietkau R; Resch A; Kulik A; Arribas L; Niehoff P; Guedea F; Schlamann A; Pötter R; Gall C; Uter W; Strnad V;
Lancet Oncol; 2017 Feb; 18(2):259-268. PubMed ID: 28094198
[TBL] [Abstract][Full Text] [Related]
11. A comparison of a brachytherapy and an external beam radiotherapy boost in breast-conserving therapy for breast cancer: local and any recurrences.
Kindts I; Verhoeven K; Laenen A; Christiaens M; Janssen H; Van der Vorst A; Van Limbergen E; Weltens C
Strahlenther Onkol; 2019 Apr; 195(4):310-317. PubMed ID: 30603857
[TBL] [Abstract][Full Text] [Related]
12. High-dose-rate brachytherapy boost effect on local tumor control in young women with breast cancer.
Guinot JL; Baixauli-Perez C; Soler P; Tortajada MI; Moreno A; Santos MA; Mut A; Gozalbo F; Arribas L
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):165-71. PubMed ID: 25446608
[TBL] [Abstract][Full Text] [Related]
13. Local recurrence rates in breast cancer patients treated with intraoperative electron-boost radiotherapy versus postoperative external-beam electron-boost irradiation. A sequential intervention study.
Reitsamer R; Peintinger F; Kopp M; Menzel C; Kogelnik HD; Sedlmayer F
Strahlenther Onkol; 2004 Jan; 180(1):38-44. PubMed ID: 14704843
[TBL] [Abstract][Full Text] [Related]
14. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
[TBL] [Abstract][Full Text] [Related]
15. [Local relapse in young (< or = 40 years) women with breast cancer after mastectomy or breast conserving surgery: 15-year results].
Fodor J; Mózsa E; Zaka Z; Polgár C; Major T
Magy Onkol; 2005; 49(3):203, 205-8. PubMed ID: 16249814
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
[TBL] [Abstract][Full Text] [Related]
17. Breast preservation in stage I and II carcinoma of the breast. The University of Chicago experience.
Heimann R; Powers C; Halpem HJ; Michel AG; Ewing CA; Wyman B; Recant W; Weichselbaum RR
Cancer; 1996 Oct; 78(8):1722-30. PubMed ID: 8859185
[TBL] [Abstract][Full Text] [Related]
18. Microscopic residual disease is a risk factor in the primary treatment of breast cancer.
Schuck A; Könemann S; Heinen K; Rübe CE; Hesselmann S; Reinartz G; Schüller P; Micke O; Schäfer U; Willich N
Strahlenther Onkol; 2002 Jun; 178(6):307-13. PubMed ID: 12122786
[TBL] [Abstract][Full Text] [Related]
19. Mammographic, pathologic, and treatment-related factors associated with local recurrence in patients with early-stage breast cancer treated with breast conserving therapy.
Kini VR; Vicini FA; Frazier R; Victor SJ; Wimbish K; Martinez AA
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):341-6. PubMed ID: 10030259
[TBL] [Abstract][Full Text] [Related]
20. Is a higher boost dose of radiation necessary after breast-conserving therapy for patients with breast cancer with final close or positive margins?
Sadek BT; Homayounfar G; Abi Raad RF; Niemierko A; Shenouda MN; Keruakous AR; Specht MC; Taghian AG
Breast Cancer Res Treat; 2015 Nov; 154(1):71-9. PubMed ID: 26420403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
